NCT04144777|Completed
Loading search results
Sponsor study identifier
interventional
84
1 country
1
Study Start
July 15, 2019
Actual (reported)Primary Completion
May 1, 2020
Actual (reported)Study Completion
May 1, 2020
Actual (reported)Solarplast is a unique mixture of antioxidant enzymes and single antioxidant molecules that are capable of attack oxidants that cause damage to the cells in the human body and cause premature aging. This mechanism may provide protection from stress, such as free radicals, heat, infection, as well as reduce inflammation and participate in the repair mechanism of the intestinal tract. Participants will consume Solarplast, or placebo, for 45 days with blood draws at day-0 and -45 in order to assess antioxidant capacity.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 1, 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 15, 2019
Actual (reported)October 23, 2019
Actual (reported)October 30, 2019
Actual (reported)May 1, 2020
Actual (reported)May 1, 2020
Actual (reported)Oxidative Stress
Analyze change in reactive oxygen species obtained from blood from baseline to 45 days using reactive oxygen species testing kits
45 days
Blood glucose
Analyze change in fasting blood glucose obtained from blood from baseline to 45 days using metabolic panel
45 days
Change in skin health using questionnaires
Analyze skin health using questionnaires
45 days
Change in joint pain using questionnaires
Analyze change in joint pain using questionnaires
45 days
Subjects will be administered one daily dose of Solarplast (100mg), in a capsule, for 45 days.
Subjects will be administered one daily dose of maltodextrin (100mg), in a capsule, for 45 days.
Subjects will take one capsule of Solarplast (100mg) daily for 45 days.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Kennesaw State University
Kennesaw, Georgia, 30144, United States
Trisha VanDusseldorp, PhD
Kennesaw State University
84 participants (actual enrollment reported by the registry).
First Submitted
October 23, 2019
First Posted
October 30, 2019
Study Start
July 15, 2019
Actual (reported)Rejuvant™ Safety and Biomarker Study
Contact the study team to confirm eligibility.
Primary Completion
May 1, 2020
Actual (reported)Study Completion
May 1, 2020
Actual (reported)Last Updated
February 15, 2021
Record last verified: 2019-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: